N/A N=211

Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops

Glaucoma

Bottom Line

View on ClinicalTrials.gov: NCT02138461 ↗

Enrolled (actual)

211

Serious AEs

0.0%

Results posted

Sep 2014

Primary outcome: Primary: Tolerability of Medications as Measured by the COMTOL Validated Instrument — 23; 50; 26; 29 percentage of patients

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: MDbackline, LLC
Primary completion: Sep 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Tolerability of Medications as Measured by the COMTOL Validated Instrument	23; 50; 26; 29; 31; 42	—

Summary

This study examines patient perceptions regarding the tolerability of two classes of glaucoma medication: bimatoprost and latanoprost.

Eligibility Criteria

Inclusion Criteria

Patients with glaucoma taking either bimatoprost or latanoprost

Exclusion Criteria

patients taking other medication or with other causes for ocular surface symptoms

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02138461). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.